JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GOLDSTEIN, M.
Right arrow Articles by FELCH, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GOLDSTEIN, M.
Right arrow Articles by FELCH, W. C., JR.
Journal of Pharmacology And Experimental Therapeutics, Vol. 171, Issue 2, 196-204, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics


REGIONAL DISTRIBUTION AND METABOLISM OF H3-TYRAMINE IN THE RAT BRAIN

MENEK GOLDSTEIN 1, BERTA ANAGNOSTE 1, AKIKO YAMAMOTO 1, and WILLIAM C. FELCH JR. 1

1 New York University School of Medicine, Department of Psychiatry and Neurology, Neurochemistry Laboratory, New York, New York

The disposition and metabolism of H3-tyramine was investigated in different regions of the central nervous system after the intraventricular injection of the labeled amine. The hypothalamus contained the highest concentration of radioactive amines. The ratio of amines to acidic-neutral metabolites was higher in the hypothalamus than in other analyzed regions of the brain. In all analyzed regions of the central nervous system, with the exception of the striatum, the major part of the radioactivity of the amine fraction was associated with H3-octopamine. In the striatum all the radioactivity of the amine fraction was associated with unchanged H3-tyramine. The deaminated H3-metabolites of tyramine were isolated and identified in different regions of the brain. The major metabolite in all analyzed regions was found to be H3-p-hydroxyphenylacetic acid and the minor was found to be H3-p-hydroxyphenylethanol. Although both H3-phydroxyphenylacetic acid and H3-p-hydroxyphenylethanol were present in the conjugated form, the percentage of the latter in this form was greater. The ratio of conjugated to nonconjugated metabolites increased with time after administration of H3-tyramine. No evidence was obtained for the presence of deaminated metabolites from H3-octopamine newly formed from H3-tyramine. After inhibition of monoamine oxidase by pheniprazine there was a several-fold increase of the radioactivity in the H3-amine fraction concomitant with a decrease in the concentration of the deaminated H3-metabolites. Inhibition of dopamine-beta-hydroxylase with disulfiram prevents the conversion of H3-tyramine to H3-octopamine, and after monoamine oxidase and dopamine-beta-hydroxylase inhibition, H3-tyramine accumulates in all H3-octopamine-containing regions of the brain.

Submitted on June 30, 1969
Accepted on October 22, 1969







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.